NEWS
Vale Biolabs Takes the Full Venture Kick on Brain Organoids
Vale Biolabs collected CHF 150,000 in Stage III Kick cash, a bet that automated brain organoids can flag CNS drug failures before trials.
Vale Biolabs collected CHF 150,000 (€164,000) from Venture Kick on November 9, 2026, the full three-stage purse for its human brain organoid platform. The check is Stage III, the last jury in a Swiss gauntlet that only pays the top after a team looks close to market.
The Schlieren company, founded in 2026 by four people, is placing a small, staged wager that lab-grown human brain tissue, automation and predictive AI can flag drug failures that animal tests miss. The sum is tiny next to a failed brain-drug trial. That mismatch is the point of the bet, not a rounding error the jury ignored.
Venture Kick Cleared Them After Three Juries
Venture Kick is a philanthropic program of the Kick Foundation, operated by Venturelab, and it is built as a filter rather than a single cheque. In 2026 it has CHF 9,580,000 to put into 283 kicks for research-based founders from Swiss universities. Money can start before a company exists, then climb only if later juries still like the case.
The path runs through three jury stages over nine months. At each stage, about half the teams that pitch move on. Stage 1 seats eight projects and pays five of them a CHF 10,000 grant that may cover business-development costs but not founder salaries or share capital. Stage 2, due within three months, pays CHF 40,000 as a convertible loan. Stage 3, due within a further six months, pays CHF 100,000 as another convertible loan, and the firm has to be incorporated to collect it. Both loans convert at the next round’s valuation with no discount and carry 5% interest.
THE THREE-STAGE KICK
| Stage | Amount | Instrument | Jury bar |
|---|---|---|---|
| Stage 1 | CHF 10,000 | Grant | Five of eight pitches; business idea |
| Stage 2 | CHF 40,000 | Convertible loan at 5% | Business case within three months |
| Stage 3 | CHF 100,000 | Convertible loan at 5% | Market-ready, company incorporated |
| Full stack | CHF 150,000 | Grant plus two loans | Survive all three juries |
CHF 10,000 plus CHF 40,000 plus CHF 100,000 is CHF 150,000, and Vale Biolabs AG took the lot. The Stage III funding notice from Venture Kick named co-founders Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano and Theodoulos Rodosthenous. Incaviglia is CEO. Damilou is listed as founding scientist. The vehicle is an AG, founded in 2026 in canton Zurich and based in Schlieren, which is the legal form Stage 3 requires.
On October 13, 2026, 27 days before that notice, Incaviglia also pitched Vale at EWOR’s Grand Pitch, a fellowship stage that put her among 11 founders. The Kick cash is still the priced wager. EWOR was a room. Stage III is a term sheet.
Why Animal Models Keep Missing Human Brain Drugs
The bet only makes sense against a grim scoreboard. The U.S. Food and Drug Administration says over 90% of drugs safe in animals still fail in people, and it now groups human cell systems, computer models and related tools under the label new approach methodologies, or NAMs. Some medicines people already use, including aspirin, might never have passed those animal tests.
Brain programs sit at the ugly end of that record. Mouse studies often start treatment before the animal shows clear disease, while human trials enroll patients who already have symptoms, a timing mismatch Stanford researchers mapped in a 2025 review of tauopathy work. A February 2026 Nature Medicine editorial logged two more late hits: Novo Nordisk’s oral GLP-1 drug semaglutide failed to slow Alzheimer’s in two phase 3 trials, and Johnson & Johnson stopped a phase 2 tau antibody, posdinemab, after a scheduled review found no slowing of cognitive decline.
Technological advances are allowing us to move beyond animal testing in drug development, which has a poor track record of predicting safety and efficacy in humans.
Marty Makary, M.D., M.P.H., FDA Commissioner, March 18, 2026 draft guidance announcement
Washington has been rewriting the vocabulary around that failure. The question for a company the size of Vale is whether a dish of human tissue can walk through the door those memos opened, or only pose beside it.
THE NAM CLOCK IN WASHINGTON
- December 29, 2022: Congress writes “nonclinical tests” into the Food, Drug, and Cosmetic Act, covering in vitro, in silico and animal work.
- April 2025: FDA publishes a roadmap to cut animal testing in nonclinical safety studies, starting with monoclonal antibodies.
- March 18, 2026: A CDER draft guidance lists organoids, spheroids and organs on chips among NAMs and sets four tests: context of use, human biological relevance, technical characterization and fit-for-purpose.
- April 20, 2026: The agency says it hit its year-one roadmap goals and posts a progress report.
- September 2026: A direct final rule swaps “animal” for “nonclinical” in drug-development regulations; comments run through December 7, 2026, and the rule is due to take effect on February 4, 2027 if it is not pulled.
That clock is the market Vale is selling into. It is still a draft clock. The March 2026 text does not qualify any brain organoid, and FDA staff have told sponsors to talk to the relevant review division about a named use, not a generic mini-brain claim.
An Automated Watch on Living Tissue
Vale grows standardized human brain organoids, miniature tissue models that reproduce some features of the human brain, then watches them over time. Automation tracks structure, activity and molecular responses before and after a candidate treatment. Those time series become training data for predictive models aimed at brain development, neurodegenerative disease and healthy ageing.
The company’s own profile is blunter than the award copy. Drug discovery, it says, still leans on animal models and endpoint assays that miss biology as it changes through time, and what is missing is scalable, standardized human-relevant data that can power AI-ready models. The target is the preclinical testing market, which that profile calls multi-billion-dollar. Alzheimer’s and Parkinson’s are named as diseases the platform could support, along with rarer brain disorders. Support is not a therapy in a vial.
Venture Kick has challenged us to think more deeply about how we build Vale Biolabs and bring our technology to the researchers who need it. The funding and feedback will help us take the next step in developing human models that can improve how we study brain diseases and test potential treatments.
Ilaria Incaviglia, Co-Founder and CEO, Vale Biolabs
The founding mix is organoid neurobiology, automation, data-science engineering and early-stage venture work. That is a product team, not a single principal investigator with a side company. The Kick notice treats the output as a platform drug developers could use earlier, so that a flop dies in a well instead of in a phase 2 readout.
Vale Biolabs receives CHF 150,000 from Venture Kick to improve brain drug development with human tissue models 🧠 https://t.co/cwxIYv8vwc
The biotech startup has secured funding to advance its platform combining lab-grown human brain tissue, automation, and predictive AI to… pic.twitter.com/319fK6CxtQ
— Venture Kick (@venturekick) November 9, 2026
The open test is simple, and it is not whether a jury in Switzerland liked the pitch. It is whether a standardized organoid time series can beat a mouse study on a compound that already failed in people. Until that comparison exists, the platform is a well-instrumented hypothesis.
The Same Protocol Still Gives Different Tissue
The scientific risk is not that organoids are imaginary. It is that they are inconsistent. Paola Arlotta, whose Harvard lab has kept organoids alive for years, puts it without romance: they are not brains. They are reductionist replicas that show some things that match and many that do not.
Barbara Treutlein, who leads a group at ETH Zurich’s Department of Biosystems Science and Engineering and co-wrote Roche’s neural organoid atlas work, said the gap in plainer lab language. What teams aim to get when they make organoids, and what they actually get, are not usually the same. Roche, ETH Zurich and Helmholtz Munich spent years stitching 26 protocols and more than 1.7 million cells into one neural organoid atlas for that reason. Comparison at that scale is the problem Vale says it will industrialize with cameras and code.
WHERE THE DISH STILL BREAKS
- Not a brain: Organoids copy some cell types and some architecture; they do not copy a working human brain, and calling them that oversells the assay.
- Protocol drift: Two labs following “the same” recipe still land on different cell mixes, which is why atlas papers exist and why a buyer will ask for lot-to-lot numbers.
- No named use yet: FDA’s draft asks for a context of use, not a general claim that mini-tissue predicts clinical success in Alzheimer’s or Parkinson’s.
- Four tests, not a vibe: Context of use, human relevance, technical characterization and fit-for-purpose are the filter a dish has to pass before it replaces a mouse in a filing.
A 2026 Cell Stem Cell perspective on organoids and organs-on-chips as NAMs listed the same unfinished work: getting the same result twice, proving the method for a stated job, and getting regulators to accept that proof. Vale’s pitch is that standardization plus automation plus a growing dataset is how a four-person AG attacks those three gaps. The Kick money buys the attack. It does not buy the proof.
What the CHF 150,000 Pays For
The Stage III notice lists three jobs for the cash, and none of them is a clinical trial. Further build-out of the automated platform comes first. Expansion of the human brain organoid models comes second. Generation of datasets to train and validate the predictive models comes third. Collaborations with research groups and industry partners ride alongside, still unnamed in the public copy.
That spend list is honest about where the company sits. Time-series phenotyping, the profile’s phrase for watching tissue as it changes, is a data business wearing a biology coat. If the wells are not comparable, the model learns noise. If the wells are comparable, the model becomes something a preclinical group might buy instead of another rodent cohort. The CHF 150,000 is seed capital for that comparison, not a verdict that the comparison already works.
Stage 1 cash could not pay founder salaries. Stage 3 cash can, because the AG exists. The practical shift inside the lab is that the next months are for making more tissue, more often, under tighter control, and for writing the kind of dataset a partner will sign a materials-transfer agreement to see. The public notice does not name a first customer.
Behind Stage III, a Larger Swiss Checkbook
Kick’s own ladder does not stop at CHF 150,000, which is why the program sells itself as “1 Million Plus.” Teams that pass Stage 2 may apply for a separate CHF 150,000 InnoBooster grant from Gebert Rüf Stiftung, a research grant stacked on top of the Kick purse, not a second copy of it. Stage 3 winners can access up to CHF 850,000 from Kickfund. Added to the Kick money and a full InnoBooster, the advertised ceiling is CHF 1,150,000.
Access is not a wire. InnoBooster is an application. Kickfund is an equity path, not another philanthropic gift, and the public Stage III notice does not say Vale has drawn either. What the jury did was stamp the file. Downstream Swiss cheques get cheaper to raise when that stamp exists, which is the quiet function of the program: a public filter that later investors can free-ride on.
For a 2026 AG with four founders, that stamp may matter more than the CHF 100,000 loan that closed the stack. Convertible paper at 5% with no discount is cheap capital. A jury that already said the team looks market-ready is a sentence other people can paste into a memo. The next priced round will reveal whether anyone outside the Kick room believes the organoids are a product.
Late to a Crowded Swiss Bench
Schlieren is not the first Swiss bench to grow human tissue for drug work, and it is not the first Kick winner in the brain. Six days before Vale’s notice, on November 3, 2026, Roche published a story on organoid atlases built with ETH Zurich and Helmholtz Munich, including a human neural atlas meant to tell labs what they actually grew. Treutlein’s line about aim versus result came from that work. The atlas is a map. Vale is trying to sell a factory that uses a map like it.
AzureCell Therapies, a University of Geneva spin-off, took CHF 150,000 from Venture Kick on July 16, 2025, for lab-grown neurons aimed at Parkinson’s. That was a therapy bet: replace damaged dopamine cells. Vale’s bet is a testing bet: watch human brain tissue so someone else’s drug dies cheaper. Same disease family, opposite customer. One sells a cell. The other sells a readout.
InSphero, a Swiss 3D-tissue company that went through Kick years earlier, said the program forced customer and market focus before the firm was even founded. Vale is running the same sequence on brain organoids, with AI as the extra layer the 2010s tissue companies did not have to pitch. The crowded bench is the constraint. Roche and ETH already publish the comparison tools. AzureCell already took the same size Kick cheque for Parkinson’s cells. A four-person AG in Schlieren has to be the shop that makes the assay boring enough to buy, which is a harder job than making it look new.
Vale now has a jury stamp, an incorporated AG, and CHF 150,000 to grow more tissue and more data. The models still have to show, on a named compound, that they catch a failure a mouse missed.
-
BUSINESS5 months agoAramco Crash Kills 14 Two Days After Oil Restart
-
NEWS6 months agoSalah Captained Egypt to Their First World Cup Win
-
GAMING2 months agoZelda’s 40th Switch 2 Ships Without a Zelda Game
-
NEWS3 months agoApple Labor Day Deals Hide June’s Memory Price Hike
-
NEWS4 months agoEl Niño Puts Israel’s Needed Winter Rain on a Flood Clock
-
GAMING2 months agoPalworld 1.0.4 Adds Palpedia Search After the 1.0 Launch
-
NEWS4 months agoSaudi Visa Routes Split Nigerian Travelers Into Two Speeds
-
BUSINESS9 months agoBAE’s 60-Year Saudi Franchise Now Runs Through Taif
